Renalytix Plc (RENXF)

Market Cap	44.17M +68.5%
Revenue (ttm)	3.30M +40.3%
Net Income	-19.90M
EPS	-0.05
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,511
Open	0.0482
Previous Close	0.0438
Day's Range	0.0482 - 0.0877
52-Week Range	0.0231 - 0.1787
Beta	1.87
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 28, 2026

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company’s products are used in kidney disease diagnosis and prognosis, cl...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2018
• Employees: 46
• Stock Exchange: OTCMKTS
• Ticker Symbol: RENXF

Financial Performance

In fiscal year 2025, Renalytix's revenue was $3.00 million, an increase of 30.43% compared to the previous year's $2.30 million. Losses were -$20.40 million, -55.16% less than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 9, 2026

Data Sources Report a data error